Please login to the form below

Not currently logged in
Email:
Password:

follicular lymphoma

This page shows the latest follicular lymphoma news and features for those working in and with pharma, biotech and healthcare.

NICE backs Roche’s Gazyvaro after initial rejection

NICE backs Roche’s Gazyvaro after initial rejection

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Roche’s Gazyvaro as a first-line treatment for lymphoma patients, reversing its earlier stance on the drug. ... Last September the cost-effectiveness watchdog turned

Latest news

  • Novartis files CAR-T therapy CTL109 in Europe Novartis files CAR-T therapy CTL109 in Europe

    as follow-up indication diffuse large B-cell lymphoma (DLBCL) which it submitted to the FDA last month. ... Kite was the first to file its new therapy in Europe, seeking approval in August for DLBCL, transformed follicular lymphoma (TFL), and primary

  • Roche's Actemra/RoActemra receives new European approval Roche's Actemra/RoActemra receives new European approval

    Gazyvaro approved for advanced follicular lymphoma. Meanwhile, the European Commission has also licensed Roche’s Gazyvaro (obinutuzumab) for patients with previously untreated advanced follicular lymphoma. ... with follicular lymphoma who did not

  • Bayer bags speedy US approval for lymphoma drug Aliqopa Bayer bags speedy US approval for lymphoma drug Aliqopa

    The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in follicular lymphoma. ... Richard Pazdur, director of the FDA's Office of Haematology and Oncology Products, said: "For patients with

  • Roche faces prospect of second Rituxan biosimilar in US Roche faces prospect of second Rituxan biosimilar in US

    Rituxan is used to treat blood cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukaemia, as well as immunological diseases such as rheumatoid arthritis, and is Roche's biggest-selling ... at the drug's pharmacological profile in

  • Kite starts EU trial of lead CAR-T therapy Kite starts EU trial of lead CAR-T therapy

    ZUMA-1 trial showed that in a heavily-treated population with refractory aggressive non-Hodgkin’s lymphoma (NHL) - with few treatment options - axi-cel achieved an overall response rate of 82%, ... Kite is currently enrolling adult patients with

More from news
Approximately 2 fully matching, plus 45 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics